BioCrossroads

Lumavate, LLC operates a cloud-based software platform that enables manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their labels into an inbound communication channel, providing end-users with essential information for product repairs, access to genuine manufacturer parts, and connections to service technicians. This service caters to various sectors, including infrastructure, outdoor industries, and healthcare, among others. Lumavate specializes in building progressive web applications (PWAs) at scale, facilitating personalized mobile experiences throughout the customer journey. By integrating smart packaging and the Internet of Things, Lumavate connects products with end-users at critical moments in their lifecycle, helping companies monetize their digital strategies and create new revenue streams. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus.

Kovina Therapeutics operates as a pre-clinical biotechnology company aims to discover a non-surgical, medical treatment for Human Papillomavirus (HPV) infections and cancers.

Novosteo Inc. is a company founded in 2017 and located in West Lafayette, Indiana, that focuses on developing and manufacturing innovative drugs aimed at healing bone fractures. The company utilizes a specialized drug discovery platform designed to target the specific needs of fracture healing. By concentrating the healing properties of its drugs at the site of the fracture, Novosteo aims to accelerate the recovery process and enhance the overall healing experience for patients. This approach seeks to mitigate the morbidity, mortality, and productivity loss associated with bone fractures, ultimately improving patient outcomes and reducing the debilitating effects that can arise from such injuries.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.

Sexton Biotechnologies is a biotechnology company founded in 2019 and based in Indianapolis, Indiana. The company specializes in developing and selling bioproduction tools for cell and gene therapy (CGT), focusing on tools and media that facilitate flexible automation and scaling of cell manufacturing processes. This innovation aims to enhance positive clinical outcomes in CGT applications. Recently, Sexton Biotechnologies raised $5 million in growth capital, marking its emergence as an independent entity following incubation by Cook Regentec. The company plans to leverage this funding to advance ongoing research and product development while expanding the commercialization of its portfolio, which includes container closure and media supplementation tools designed specifically for CGT bioproduction.

Lumavate, LLC operates a cloud-based software platform that enables manufacturers to enhance customer experiences through mobile engagement. The platform allows product manufacturers and brands to transform their labels into an inbound communication channel, providing end-users with essential information for product repairs, access to genuine manufacturer parts, and connections to service technicians. This service caters to various sectors, including infrastructure, outdoor industries, and healthcare, among others. Lumavate specializes in building progressive web applications (PWAs) at scale, facilitating personalized mobile experiences throughout the customer journey. By integrating smart packaging and the Internet of Things, Lumavate connects products with end-users at critical moments in their lifecycle, helping companies monetize their digital strategies and create new revenue streams. Founded in 2015 and based in Carmel, Indiana, Lumavate was previously known as LabelNexus.

OmniVis operates a portable pathogen detection platform that allows for the rapid and accurate measurement of pathogens in various environments, particularly in food processing facilities. The company provides an easy-to-use hardware device in conjunction with disposable test kits that can analyze swabs or liquid samples. This streamlined process reduces the pathogen detection time to just 30 minutes, making it both efficient and cost-effective for health organizations. By focusing on user-friendly technology, OmniVis aims to enhance the accuracy of pathogen detection while ensuring affordability and simplicity in its application.

Scioto Biosciences, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, founded in 2017. The company develops an Activated Bacterial Therapeutics (ABT) platform designed to deliver live bacteria to the gut, focusing on enhancing the efficacy of microbiome therapeutics. This innovative platform allows for the sustained presence of active therapeutic bacteria in the gastrointestinal tract, promoting adhesion to the intestinal mucosa. Scioto Biosciences aims to create transformative therapies that can improve healing for various conditions, particularly those related to the central nervous system and gastrointestinal disorders. The company's research emphasizes optimizing therapeutic functions, increasing gut survival, and facilitating mucosal thickening, which may lead to better treatment outcomes in severe gut injury models.

Allinaire Therapeutics, LLC is a biotechnology company based in Cleveland, Ohio, focused on developing innovative therapeutics for chronic obstructive pulmonary disease (COPD) and other pulmonary conditions, including pulmonary arterial hypertension (PAH). Founded in 2015, the company leverages research conducted by its scientific founders, Irina Petrache, MD, and Matthias Clauss, Ph.D., who identified a novel therapeutic target critical to the development and progression of lung diseases. Allinaire Therapeutics aims to create treatment options that could significantly enhance clinical outcomes for patients suffering from these debilitating respiratory illnesses.

SonarMed, Inc. is a medical device company founded in 2005 and based in Carmel, Indiana. It specializes in the placement and monitoring of endotracheal tubes, which are essential for patients who cannot breathe independently. The company's flagship product, the SonarMed AirWave, is a non-invasive device that utilizes acoustic reflectometry technology to provide real-time monitoring of endotracheal tube position and function. This innovation allows healthcare providers to detect potentially dangerous conditions related to tube placement, ultimately enhancing patient safety and improving the quality of care. By offering a more comprehensive solution for managing breathing tubes, SonarMed aims to benefit both patients and healthcare professionals while also contributing to cost reduction in medical care.

Scioto Biosciences, Inc. is a clinical-stage biotechnology company based in Indianapolis, Indiana, founded in 2017. The company develops an Activated Bacterial Therapeutics (ABT) platform designed to deliver live bacteria to the gut, focusing on enhancing the efficacy of microbiome therapeutics. This innovative platform allows for the sustained presence of active therapeutic bacteria in the gastrointestinal tract, promoting adhesion to the intestinal mucosa. Scioto Biosciences aims to create transformative therapies that can improve healing for various conditions, particularly those related to the central nervous system and gastrointestinal disorders. The company's research emphasizes optimizing therapeutic functions, increasing gut survival, and facilitating mucosal thickening, which may lead to better treatment outcomes in severe gut injury models.

SpeechVive Inc. is a medical technology company based in Lafayette, Indiana, founded in 2011. The company focuses on developing a wearable device aimed at improving communication for individuals with Parkinson's disease. This innovative device enhances patients' ability to hear by reducing background noise, which in turn increases their speech volume and clarity. By addressing communication challenges faced by those with Parkinson's, SpeechVive aims to help users lead more normal and fulfilling lives.

Calibrium is an emerging privately held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

Assembly Pharmaceuticals is a virology-focused biopharmaceutical company with a discovery platform and programs based on proprietary Core Protein Allosteric Modulators (CpAMs) for the treatment of viral infections, starting with hepatitis B (HBV). CpAMs can alter the activities of the HBV core protein, a unique viral protein with no human analogue that is involved in multiple stages of the HBV life cycle. In contrast to current therapies that only suppress HBV, Assembly Pharmaceutical’s CpAMs may have curative potential by eliminating the viral reservoir in infected individuals. Hepatitis B infection has a worldwide prevalence of over 350 million and more than 600,000 people die every year from complications associated with chronic HBV. Assembly has operations in Indiana and San Francisco.

Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative compounds for cancer treatment. The company's lead drug candidate, APX3330, is an oral anticancer agent designed to target the APE1/Ref-1 redox protein, which is implicated in various cancers, including those of the colon, lung, breast, and pancreas. Founded in 2007 and headquartered in Indianapolis, Indiana, Apexian Pharmaceuticals emerged from the research of Dr. Mark R. Kelley, whose work on APE1/Ref-1 protein signaling has informed the company's therapeutic approach. Formerly known as ApeX Therapeutics, Apexian Pharmaceuticals emphasizes its commitment to advancing novel cancer therapies.

Diagnotes, Inc. is a digital healthcare company that develops a clinical communication and collaboration platform designed to enhance communication within the healthcare sector. Founded in 2010 and based in Indianapolis, Indiana, Diagnotes offers a mobile and web-based application that aligns with the natural communication habits of healthcare professionals and their patients. The platform enables secure messaging, provider scheduling, patient data management, discussion documentation, and patient engagement, facilitating efficient communication among patients, physicians, care teams, hospitals, and health systems. Diagnotes serves a diverse client base, including large health systems, specialty hospitals, long-term care facilities, and behavioral health organizations. Its capabilities extend to telehealth consultations, enabling specialists to connect with patients in remote areas through live video.

SonarMed, Inc. is a medical device company founded in 2005 and based in Carmel, Indiana. It specializes in the placement and monitoring of endotracheal tubes, which are essential for patients who cannot breathe independently. The company's flagship product, the SonarMed AirWave, is a non-invasive device that utilizes acoustic reflectometry technology to provide real-time monitoring of endotracheal tube position and function. This innovation allows healthcare providers to detect potentially dangerous conditions related to tube placement, ultimately enhancing patient safety and improving the quality of care. By offering a more comprehensive solution for managing breathing tubes, SonarMed aims to benefit both patients and healthcare professionals while also contributing to cost reduction in medical care.

Bioscience Vaccines, Inc. is a life sciences company based in West Lafayette, Indiana, specializing in the development of vaccine adjuvants and companion products aimed at preventing infectious diseases. The company is known for its proprietary technology, the Matrix Immune Modulator, which has its origins in the research conducted by Dr. Mark Suckow at the University of Notre Dame and builds upon discoveries made at Purdue University. This innovative technology has the potential to enhance existing FDA-approved vaccines for both human and animal diseases, and the company is also exploring immunotherapeutic treatments for cancer using tissue vaccines.

ImmuneWorks, Inc. is a biotechnology company based in Indianapolis, Indiana, founded in 2006. The company focuses on developing immune tolerance therapies aimed at treating idiopathic pulmonary fibrosis and other fibrotic lung diseases. ImmuneWorks is grounded in the discovery that antigen-specific autoimmunity contributes to the disease in more than half of idiopathic pulmonary fibrosis cases. By utilizing advanced biotechnological procedures, the company seeks to create safe and effective treatments for patients suffering from serious autoimmune diseases affecting the lungs, ultimately aiming to enhance their quality of life.

FlowCo is a medical device company, develops products to improve the flow of blood through the vascular system.

CS-Keys is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer.